摘要
目的探析晚期肝癌患者应用盐酸多柔比星脂质体治疗的临床效果。方法选取濮阳市油田总医院2015年2月至2019年2月间收治的晚期肝细胞癌患者共计84例作为研究对象,按照随机数字表法分为对照组(42例)和观察组(42例),对照组给予氟尿嘧啶治疗,观察组给予盐酸多柔比星脂质体治疗,比较两组疾病治疗效果、治疗前后标志物水平、生活质量及不良反应。结果与对照组相比,观察组客观有效率(ORR)明显更高,差异有统计学意义(P<0.05);与治疗前相比,两组治疗后胸苷激酶(TK)、甲肽蛋白(AFP)和血管内皮生长因子(VEGF)水平明显下降,差异有统计学意义(P<0.05),与对照组相比,观察组治疗后水平明显更低,差异有统计学意义(P<0.05);与治疗前相比,两组治疗后生活质量综合评定问卷(GQOLI-74)各项目评价分数明显提高,差异有统计学意义(P<0.05),与对照组相比,观察组治疗后评分明显更高,差异有统计学意义(P<0.05);观察组不良反应发生率明显更低,差异有统计学意义(P<0.05)。结论在晚期原发性肝细胞癌的治疗中使用盐酸多柔比星,能够提高临床疗效,调节标志物水平,减少不良反应,对患者生活质量有积极提升价值。
Objective To explore the clinical effect of doxorubicin hydrochloride liposome in advanced hepatocellular carcinoma patients.Methods A total of 84 patients with advanced hepatocellular carcinoma admitted to Puyang Oilfield General Hospital from February 2015 to February 2019 were selected as the research subjects,and they were divided into the control group(42 cases)and the observation group(42 cases)according to the random number table method.The control group was given fluorouracil treatment,the observation group was given doxorubicin hydrochloride liposome treatment.The treatment effects,marker levels before and after treatment,quality of life and adverse reactions were compared between the two groups.Results Compared with the control group,the objective response rate(ORR)of the observation group was significantly higher(P<0.05).Compared with before treatment,the levels of thymidine kinase(TK),alpha-peptide protein(AFP)and vascular endothelial growth factor(VEGF)in the two groups were significantly decreased after treatment(P<0.05),and the observation group had significantly lower levels after treatment(P<0.05).Compared with before treatment,the scores of the comprehensive assessment of quality of life(GQOLI-74)in the two groups after treatment were significantly improved(P<0.05),and the scores in the observation group after treatment were significantly higher(P<0.05).Compared with the control group,the incidence of adverse reactions in the observation group was significantly lower(P<0.05).Conclusion The use of doxorubicin hydrochloride in the treatment of advanced primary hepatocellular carcinoma can improve clinical efficacy,regulate marker levels,reduce adverse reactions,and play an important role in improving patients’quality of life.
作者
段丛迪
张洪川
DUAN Congdi;ZHANG Hongchuan(Puyang Oilfield General Hospital,Puyang Henan 457001,China)
出处
《临床研究》
2022年第3期80-83,共4页
Clinical Research
关键词
盐酸多柔比星
肝细胞肝癌
临床疗效
甲胎蛋白
生活质量
doxorubicin hydrochloride
hepatocellular carcinoma
clinical efficacy
alpha-fetoprotein
quality of life
